Department of Radiology, University Hospitals of Southampton, Tremona Road, Southampton, Hampshire SO16 6YD, UK.
Department of Liver Transplantation, Hepatology and Infectious Diseases, Division of Diagnostic Imaging and Intervention, Pisa University Hospital and School of Medicine, Building No. 29, 2nd Floor, Via Paradisa 2, IT-56124 Pisa, Italy.
Nat Rev Clin Oncol. 2015 Mar;12(3):175-86. doi: 10.1038/nrclinonc.2014.237. Epub 2015 Jan 20.
Image-guided ablation (IGA) techniques have evolved considerably over the past 20 years and are increasingly used to definitively treat small primary cancers of the liver and kidney. IGA is recommended by most guidelines as the best therapeutic choice for patients with early stage hepatocellular carcinoma (HCC)-defined as either a single tumour smaller than 5 cm or up to three nodules smaller than 3 cm-when surgical options are precluded, and has potential as first-line therapy, in lieu of surgery, for patients with very early stage tumours smaller than 2 cm. With regard to renal cell carcinoma, despite the absence of any randomized trial comparing the outcomes of IGA with those of standard partial nephrectomy, a growing amount of data demonstrate robust oncological outcomes for this minimally invasive approach and testify to its potential as a standard-of-care treatment. Herein, we review the various ablation techniques, the supporting evidence, and clinical application of IGA in the treatment of primary liver and kidney cancers.
图像引导消融 (IGA) 技术在过去 20 年中得到了极大的发展,越来越多地用于明确治疗小的原发性肝和肾肿瘤。IGA 被大多数指南推荐为早期肝细胞癌 (HCC)患者的最佳治疗选择 - 定义为单个肿瘤小于 5 厘米或多达三个结节小于 3 厘米,当手术选择不可行时,并且对于非常早期的肿瘤小于 2 厘米的患者,有替代手术的一线治疗潜力。关于肾细胞癌,尽管没有任何随机试验比较 IGA 与标准部分肾切除术的结果,但越来越多的数据证明了这种微创方法的强大肿瘤学结果,并证明了其作为标准治疗的潜力。本文综述了各种消融技术、IGA 在治疗原发性肝和肾癌中的支持证据和临床应用。